Cargando…

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma

BACKGROUND: Midazolam (MDZ) is an anaesthetic that is widely used for anxiolysis and sedation. More recently, MDZ has also been described to be related to the outcome of various types of carcinomas. However, how MDZ influences the progression of hepatocellular carcinoma (HCC) and its effects on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Junwei, Zheng, Zhiying, Li, Xian, Huang, Tian, Rong, Dawei, Liu, Xinyang, Qin, Miaomiao, Wang, Yuliang, Kong, Xiangyi, Song, Jinhua, Lv, Chengyu, Pan, Xiongxiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555186/ https://www.ncbi.nlm.nih.gov/pubmed/36224624 http://dx.doi.org/10.1186/s12935-022-02735-3

Ejemplares similares

Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway
por: Guangshun, Sun, et al.
Publicado: (2022)

Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing
por: Hao, Xiaopei, et al.
Publicado: (2022)

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
por: Kong, Xiangyi, et al.
Publicado: (2022)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma
por: Qin, Miaomiao, et al.
Publicado: (2021)

Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus
por: Meng, Qiuxing, et al.
Publicado: (2021)

Natural killer cells in antitumour adoptive cell immunotherapy
por: Laskowski, Tamara J., et al.
Publicado: (2022)

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
por: Sun, Guangshun, et al.
Publicado: (2022)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
por: Kato, Ryoji, et al.
Publicado: (2020)

Antitumour Antibiotics
por: Fox, B. W.
Publicado: (1979)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

Dexmedetomidine-midazolam versus Sufentanil-midazolam for Awake Fiberoptic Nasotracheal Intubation: A Randomized Double-blind Study
por: Li, Cheng-Wen, et al.
Publicado: (2015)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
por: Leclerc, Marine, et al.
Publicado: (2019)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Antitumour activity of peroxidases.
por: Everse, K. E., et al.
Publicado: (1985)

The antitumour activities of statins
por: Takahashi, H.K., et al.
Publicado: (2007)

SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo
por: Berthois, Y, et al.
Publicado: (2003)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

Vitamin E (α-Tocopherol) Exhibits Antitumour Activity on Oral Squamous Carcinoma Cells ORL-48
por: Zulkapli, Rahayu, et al.
Publicado: (2016)

The antitumour effect of galangin and luteolin with doxorubicin on chemically induced hepatocellular carcinoma in rats
por: Atwa, Gamal, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
por: Fujiwara, Kentaro, et al.
Publicado: (2014)

Tin-based Antitumour Drugs
por: Gielen, Marcel
Publicado: (1994)

The realisation of targeted antitumour therapy
por: Bicknell, R
Publicado: (2005)

Antitumour Drug-Radiation Interactions
por: Carmichael, J.
Publicado: (1992)

An Overview of Antitumour Activity of Polysaccharides
por: Jin, Hongzhen, et al.
Publicado: (2022)

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
por: Huang, Jumin, et al.
Publicado: (2022)

PTBP1 is necessary for dendritic cells to regulate T‐cell homeostasis and antitumour immunity
por: Geng, Guangfeng, et al.
Publicado: (2021)

Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo
por: Bannon, J H, et al.
Publicado: (2007)

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
por: Li, Hongwen, et al.
Publicado: (2023)

Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (Review)
por: Pan, Jing-Hua, et al.
Publicado: (2018)

Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells
por: Gao, Wanfeng, et al.
Publicado: (2019)

Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review)
por: Sun, Guangshun, et al.
Publicado: (2022)

Metabonomics applied in exploring the antitumour mechanism of physapubenolide on hepatocellular carcinoma cells by targeting glycolysis through the Akt-p53 pathway
por: Ma, Ting, et al.
Publicado: (2016)

Targeted antitumour therapy – future perspectives
por: Ranson, M, et al.
Publicado: (2005)

The Chemistry of Antitumour Antibiotics, Vol. I
por: Fox, B. W.
Publicado: (1979)

Cimetidine enhancement of cyclophosphamide antitumour activity.
por: Dorr, R. T., et al.
Publicado: (1982)

Antitumour Effects of Astaxanthin and Adonixanthin on Glioblastoma
por: Tsuji, Shohei, et al.
Publicado: (2020)

Dynamics of an Antitumour Model with Pulsed Radioimmunotherapy
por: Wang, Gang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jpabq88ej5nu5j2kqr4cu5v7f1